Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis, and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
Company Details
- Employees
- 176
- Founded
- -
- Address
- 2929 Arch St,
- Phone
- +1 610 977 2422
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cabalettabio.com
- HQ
- Philadelphia, Pennsylvania
Cabaletta Bio Questions
Cabaletta Bio's helpline number is +1 610 977 2422
Cabaletta Bio's website is cabalettabio.com
Cabaletta Bio's LinkedIn profile is https://www.linkedin.com/company/cabalettabio
Cabaletta Bio has
176 employees.
View email and phone details for 176
employees at Cabaletta Bio.
Cabaletta Bio's industry is
Biotechnology Research
Cabaletta Bio's top competitors are
Allogene Therapeutics,
Century Therapeutics, Inc,
Vertex Pharmaceuticals,
Spark Therapeutics, Inc.,
Adaptimmune,
Interius Biotherapeutics,
Passage Bio,
Kyverna Therapeutics,
Carisma Therapeutics,
Verismo Therapeutics.
Cabaletta Bio's categories are Biotechnology Research
Cabaletta Bio's founding year is 2017
